IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC
Yazar
Barrios, C. H.
Spigel, D.
de Marinis, F.
Giaccone, G.
Reinmuth, N.
Vergnenegre, A.
Morise, M.
Felip, E.
Andric, Z. G.
Geater, S.
Mocci, S.
McCleland, M.
Enquist, I.
Komatsubara, K. M.
Deng, Y.
Kuriki, H.
Wen, X.
Jassem, J.
Herbst, R. S.
Ozguroglu, M.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]